A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Public ClinicalTrials.gov record NCT06079398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 Years of Age) With Achondroplasia Followed by an Open Label Extension (OLE) Period
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Study identification
- NCT ID
- NCT06079398
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 0 Years to 2 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2024
- Primary completion
- Nov 30, 2027
- Completion
- Nov 30, 2028
- Last update posted
- Apr 7, 2026
2024 – 2028
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascendis Investigational Site | Saint Paul | Minnesota | 55102 | Recruiting |
| Ascendis Investigational Site | Houston | Texas | 77030 | Recruiting |
| Ascendis Investigational Site | Madison | Wisconsin | 53705 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
Recently updated Achondroplasia trials
Other public records listing Achondroplasia. Sorted by last update posted; newest first. Not a recommendation.
- NCT06842355: A Study of TYRA-300 in Children With Achondroplasia: BEACH301 Recruiting
- NCT06168201: VIrtual STudy in Achondroplasia for the US (VISTA) Recruiting
- NCT07169279: Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) Recruiting
- NCT07441876: Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia Recruiting
- NCT02597881: Achondroplasia Natural History Multicenter Clinical Study Recruiting
- NCT03989947: An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06079398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2026 · Synced Jul 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06079398 live on ClinicalTrials.gov.